Antiparkinson agent. Idiopathic Parkinson's disease, in particular to reduce off-period in patients who previously have been treated with levodopa/decarboxylase inhibitors, or with levodopa alone and who have experienced motor fluctuations. The experience is limited with 'Sinemet CR' and 'Half Sinemet CR' in patients who have not been treated with levodopa before.
This prospective study will investigate the characteristics of mRCC patients at time of CR in comparison with mRCC patients non on CR treated with Sunitinib...
The FDA has announced that it has removed the clinical hold on its adaptive Phase III trial of I.V. CR...
Pfizer has announced top-line results from a double-blind Phase III study evaluating Lyrica (pregabalin controlled-release CR) formulation in adult patients...
Cara Therapeutics announced positive top-line data from the adaptive Phase II/III trial of I.V. CR 845 in patients undergoing abdominal...
This systematic review and meta-analysis aimed to determine the effectiveness of brentuximab vedotin (BV) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL) in the clinical practice setting using most recent results.